Zydus New Jersey Office Completes USFDA Pharmacovigilance Inspection With Nil Observations
New Delhi: The US Food and Drug Administration (USFDA) has concluded an onsite inspection of the pharmacovigilance and post-marketing surveillance system at Zydus Lifesciences' office in New Jersey, USA, with nil observations, the company said in a regulatory disclosure.
According to the company, the USFDA conducted the inspection from September 22 to September 25, 2026, covering its pharmacovigilance and post-marketing surveillance system.
The inspection concluded with nil observations, Zydus said.
Zydus Lifesciences is a global life-sciences company involved in discovering, developing, manufacturing and marketing healthcare therapies. According to its official website, the Zydus Group has manufacturing sites and research facilities across India as well as in the US and Brazil, with a presence in regulated markets including the US and Europe and in several emerging markets. The group’s areas of research include cardio-metabolic diseases, inflammation and immunology, neurosciences, oncology and rare diseases, along with biologics, vaccines and other healthcare products.
